SHARON, Pa., April 21 /PRNewswire-FirstCall/ -- NanoLogix, Inc., (Pink Sheets: IFEC), a Nanobiotechnology company engaged in the research, development and commercialization of technologies for the production of bacteria and disease testing kits, alternative sources of fuel, cancer therapy and remediation of toxic materials, announced the results of a study which confirms that disseminated MAC and M. simiae disease exist among AIDS patients. The study was recently published in the Indian Journal of Tuberculosis (Indian J Tuberc 2005; 52:21-26), and a presentation made at the 58th National Conference on Tuberculosis & Chest Diseases held in Mumbai from 1st to 4th January, 2004.

Link for study: http://www.biotechstocksignals.com/ifecstudy.pdf

NanoLogix's "Identikit" has shown great promise in detecting the presence of Mycobacterium avium complex (MAC) infection. The methodology provides for early detection of these pathogens in sputum and stool samples; thus allowing for treatment before the infection spreads throughout the body. Early detection of Mycobacterium avium complex (MAC) infection is rapidly becoming important, especially for those with AIDS who are living longer due to new methods of treatment. The study, conducted by a team in the Department of Microbiology, Mahatma Gandhi Institute of Medical Sciences, Sevagram between August 2001 and December 2002 was recently published. The team has documented that Mycobacterium avium complex (MAC) infection was present in several patients with AIDS through the testing of blood, sputum, peritoneal fluid, and stool samples with various culturing, isolation and identification techniques and methods. Out of 167 patients tested positive for HIV, blood samples from 71 were cultured for mycobacteria and 67 of these were also clinically diagnosed as cases of either pulmonary and/or extrapulmonary tuberculosis. The high prevalence of MAC infection in AIDS patients highlights the need for a worldwide mandate to test AIDS patients using NanoLogix's Identikit.

NanoLogix recently announced that it has received notification from the U.S. Food and Drug Administration Center for Devices and Radiological Health ("FDA"), of registration of the company and its initial product line for biophasic system devices. Because it was categorized as a medical device that did not require the standard lengthy FDA approval process, NanoLogix is beginning the production, marketing and commercializing of its Identikit biophasic system devices to cultivate and identify certain pathogenic microorganisms for medical purposes.

MAC is the primary bacterial infection associated with "wasting syndrome" of HIV/AIDS patients and is the leading cause of death among these patients worldwide. MAC is routinely resistant to anti-tuberculosis drugs and there has been no standardized method for determining antibiotic sensitivity. In HIV/AIDS patients, MAC is usually diagnosed after symptoms appear. The diagnostic screen utilizes a blood test. At this time, mortality is very high and time to death is estimated at four months. "With NanoLogix's Identikits, MAC could be detected significantly sooner than expected for normal culture techniques," stated Paul Hyman, Ph.D. Dr. Hyman is the primary investigator in NanoLogix's ongoing validation studies.

"Dr. Hyman's validation of NanoLogix's patented technology and the subsequent FDA registration clearly show that we can identify a costly disease in a fraction of the time," commented Dr. Mitchell Felder, Chief Executive Officer of NanoLogix. "These results may also have enormous implications in the treatment of TB, AIDS and MAC sufferers, as antibiotic-sensitivity tests can now be performed early enough to make a difference in these patients," he added.

According to estimates from the UNAIDS/WHO AIDS Epidemic Update (December 2004), 37.2 million adults and 2.2 million children were living with HIV at the end of 2004. This is more than 50% higher than the figures projected by WHO in 1991 on the basis of the data then available. During 2004, some 4.9 million people became infected with the human immunodeficiency virus (HIV), which causes AIDS.

The year also saw 3.1 million deaths from AIDS - a high global total, despite antiretroviral (ARV) therapy, which reduced AIDS-related deaths in the richer countries. Deaths among those already infected will continue to increase for some years even if prevention programs manage to cut the number of new infections to zero. However, with the HIV-positive population still expanding the annual number of AIDS deaths can be expected to increase for many years, unless early diagnosis and a more effective provision of ARV medication begins to slow the death rate.

Published data shows that 30% of the individuals that have HIV/Aids have Tuberculosis (TB). It has also been estimated by world health authorities that more than 70 percent of AIDS patients harbor an MAC infection. It has been shown that MAC also causes opportunistic infections among non-HIV infected pediatric and elderly persons. NanoLogix's technology allows for the rapid culturing and identification of MAC. It will also provide viable treatment options by testing the particular strain's antibiotic sensitivity. By using saliva or stool samples, this process could identify an infection as much as 10 months before the bacterium could be found in blood samples and well before symptoms begin.

Tuberculosis kills more people each year than all of the other infectious diseases combined and millions of people will die this year because of TB. Tuberculosis (TB) is a highly contagious disease transmitted through the air contaminated with droplets released from the lungs. TB strikes people in their most productive years, ages 15 to 44. Of the 2 billion people infected with TB, 200 million worldwide will develop active TB and then be able to infect others. The key to controlling the spread of TB is accurate and fast diagnosis so that treatment can begin. Testing for TB has become mandatory when related to immigration in most countries.

NanoLogix is very pleased with the sophisticated advances in its Nanobiotechnology research and development efforts in its day-to-day practice of medicine. A complete report on NanoLogix can be found at: http://www.biotechstocksignals.com/ifec.pdf

About NanoLogix

NanoLogix, Inc., formerly known as InfectTech, Inc. http://www.infectech.com/ , is a technology application innovator of biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally-friendly energy sources. NanoLogix is also engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. The Company's 31 patents can be viewed by visiting http://www.infectech.com/intellectual_property.php .

About Nanotechnology

The convergence of science, medicine and technology is on the cusp of yielding extraordinary breakthroughs. Today, patents that were once designed to identify bacteria have widespread applications across multiple markets. At the heart of this convergence is nature. All things begin and end with the building blocks of life. NanoLogix's portfolio of 31 patents have yielded a method vital to the development of biophasic system devices intended for medical purposes to cultivate and identify certain pathogenic microorganisms. The devices contain one or more components that suppress the growth of certain microorganisms while either promoting or not affecting the growth of other microorganisms. The FDA registered devices aid in the diagnosis of disease caused by the pathogenic microorganisms. Additional areas include: a method for low cost hydrogen production, a genomic cancer therapy and methods for cleaning up toxic environments using bioremediation.

NanoLogix's patents have nanotechnology applications in medical drugs/devices, bio-defense sensors, hydrogen production, cancer treatment and bioremediation. Nanotechnology applications include Biochips embedded in small transportable devices for rapid bacteria identification of disease causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for rapid environmental microbial monitoring with bio-defense implications. Its hydrogen bioreactor research is designed to assist in worldwide energy independence and reduce pollution using renewable, environmentally-friendly energy sources. NanoLogix's FDA registered diagnostic test kits are designed to be used for the rapid identification of infectious human diseases and identify 34 disease-producing bacteria, including Tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), Pseudomonas, and Nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing surgery. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. It therefore serves as the foundation for cancer therapy. NanoLogix's other patents include technology designed for use in the bioremediation of contaminated soil and water.

Source: NanoLogix, Inc.

CONTACT: Dr. Mitchell S. Felder of NanoLogix, Inc., +1-724-346-1302

Web site: http://www.infectech.com/
http://www.biotechstocksignals.com/ifecstudy.pdf
http://www.infectech.com/intellectual_property.php